A study published in the Journal of Allergy and Clinical Immunology aimed to assess the efficacy and safety of using ruxolitinib, a Janus-associated kinase inhibitor, in treating patients with severe COVID-19. Patients aged 18 years and up diagnosed with severe COVID-19 based on Chinese management guidelines were recruited for this study. The study participants were randomly placed into two groups: a group treated with ruxolitinib and standard COVID-19 care and a group with a placebo treatment of vitamin C and standard care. It was determined that although ruxolitinib treatment did not result in significantly quicker clinical improvement, the ruxolitinib recipients exhibited a numerically accelerated clinical improvement, meaning that more patients who received ruxolitinib demonstrated a quicker recovery from lymphopenia and tomography improvement than the number of patients in the placebo group. No safety concerns resulted from ruxolitinib use.